IPO Digest — June 16, 2026: Quiet Debuts, Active Hong Kong Pipeline
A-share and Hong Kong calendars showed no June 16 debuts, but A-share payment events and five HKEX filing/hearing updates kept the IPO pipeline active.
June 16 at a glance
The June 16 IPO tape was quiet on actual debuts: the A-share calendar showed no new-share subscription or listing item, while Eastmoney's Hong Kong IPO calendar showed no new HK listing for the day. The action was instead in payments and Hong Kong pipeline updates: two A-share IPOs moved to allotment-payment day, and five HKEX candidates either filed or advanced their application files as of the evening Hong Kong session. 12
| Market | June 16 verified event | What changed | Immediate next step |
|---|---|---|---|
| A-share | 0 new subscriptions; 0 new listings | Huike Co. (001399) and Zhenbao Technology (688797) had winning-number/payment events; Jihechang (920193) is scheduled for June 17 subscription at RMB 8.52. 1 | Watch June 17 BSE subscription flow and later listing dates for Huike/Zhenbao. |
| Hong Kong | 0 new listings | HKEX calendar showed no debut; pipeline activity came from filings and post-hearing materials rather than first-day trading. 2 | Track offer terms, pricing ranges, and hearing updates. |
Status labeling for this issue: all Hong Kong names below are in the "pricing not yet confirmed" bucket unless otherwise stated. None of the entries below had first-day close data on June 16.
Hong Kong pipeline: filings and hearing updates
| Company | Market / status on June 16 | Sponsor(s) | Core business | Metric worth noting | Watchpoint |
|---|---|---|---|---|---|
| Taotao Vehicles (301345.SZ) | Third submission to HKEX Main Board | CITIC Securities | Outdoor recreation and electric mobility products, including low-speed electric vehicles, electric two-wheelers and powersports vehicles. 3 | Prospectus-based media summary says Taotao ranked No. 1 globally in the low-speed electric vehicle industry by 2025 revenue, with about 10.9% share; 2025 revenue was about RMB 3.941B and profit about RMB 816M. 3 | A+H valuation and U.S. exposure: more than 97% of 2025 revenue came from overseas markets, with the U.S. the largest export destination. 3 |
| Sifang Automation (601126.SH) | H-share application to HKEX Main Board | Huatai International | New power-system solutions, protection and automation, smart O&M, power electronics, primary-secondary integration and energy-storage systems. 4 | Frost & Sullivan data cited in the filing summary puts Sifang at No. 2 in China's protection and automation solutions market in 2025, with a 10.3% share. 5 | The A+H thesis depends on whether overseas capital gives a premium for grid automation, AI data-center power infrastructure and new-energy system exposure. |
| Baige Online | Post-hearing information pack / passed HKEX hearing | CMBC Capital and BOCI Asia | Technology-enabled insurance intermediary services: scenario insurance distribution, precision marketing, digital solutions and TPA services. 6 | A separate Eastmoney analysis shows revenue rising from RMB 660M in 2023 to RMB 1.227B in 2025, while policies sold fell from 1.968B to 494M over the same period. 7 | Quality of growth: investors should separate commission revenue growth from the sharp drop in policy volume, especially in travel-scenario products. |
| Shanghai Junsai Bio-B | Re-submitted HKEX Main Board application | CITIC Securities | Cell-therapy biotech focused on solid tumors; core candidate GC101 is a TIL therapy for advanced melanoma. 8 | The company is still pre-revenue; 2024 and 2025 losses were about RMB 164M and RMB 233M, and 2025 R&D cost was about RMB 115M. GC101 is expected to submit a BLA in September 2026. 8 | This is a binary clinical/regulatory watch: the September BLA target matters more than near-term revenue multiples. |
| Savewo Group | Submitted HKEX GEM application | Baihui Capital | Hong Kong personal protection and healthcare products manufacturer/distributor, led by SAVEWO® disposable masks and related healthcare products. 9 | FY2026 revenue was HKD 75.543M and profit was HKD 16.781M; the company ranked No. 1 in Hong Kong's mask and respirator market by revenue with about 14.1% share. 9 | GEM liquidity and post-pandemic demand normalization are the key filters; the market-share headline needs to be read against a smaller mask-market baseline. |
What to track next
- A+H pipeline is widening, but not all A+H stories rhyme. Taotao is an export-driven consumer/mobility manufacturer; Sifang is a grid-automation and power-infrastructure supplier. Both are already A-share listed, but their Hong Kong investor base will likely price very different risks: U.S. trade exposure for Taotao, and grid/data-center capex durability for Sifang. 35
- Junsai Bio-B is a timing story. With no product sales and a September 2026 BLA target for GC101, investors will be underwriting clinical/regulatory probability, cash runway and the scarcity value of its TIL platform rather than conventional earnings. 8
- A-share trading catalysts resume quickly. June 16 had no A-share new subscription or listing in the captured calendar, but Jihechang (920193) is scheduled for June 17 subscription, keeping the BSE small-cap IPO tape active. 1
This digest is for market monitoring only and is not investment advice. Figures are as reported in the cited sources available by the June 16 evening publication window; offer sizes and valuation metrics remain unavailable for the unpriced Hong Kong applications above.
References
- 1Eastmoney A-share new-stock calendar
stock.eastmoney.com
- 2Eastmoney Hong Kong IPO calendar
hk.eastmoney.com
- 3Sina / Zhitong: Taotao Vehicles third HKEX filing
finance.sina.com.cn
- 4HKEX Chinese application proof: Sifang Automation
www1.hkexnews.hk
- 5Sina / Guandian: Sifang submits HKEX application
finance.sina.cn
- 6HKEX post-hearing information pack: Baige Online
www1.hkexnews.hk
- 7Eastmoney: Baige Online IPO analysis
finance.eastmoney.com
- 8Sina / Caitongshe: Junsai Bio re-files HKEX application
finance.sina.cn
- 9Sina: Savewo Group submits GEM application
finance.sina.com.cn
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.